GoldenGolden
Advanced Search
FORMA Therapeutics

FORMA Therapeutics

A Forma Therapeutics is a bio-pharmaceutical company that focuses on therapeutics for rare hematological diseases and cancer.

FORMA Therapeutics is a company founded in 2007 and is headquartered in Watertown, Massachusetts. The company researches, develops, and commercializes novel therapeutics to transform the lives of patients with rare hematologic diseases and cancers.

Timeline

June 14, 2021
Forma Therapeutics announces the appointment of John E. Bishop, Ph.D., as Chief Technology Officer
December 19, 2019
FORMA Therapeutics raises a $100,000,000 series D round from RA Capital Management.
December 1, 2009
FORMA Therapeutics raises a $25,500,000 series B round from Lilly Ventures.
December 2009
FORMA Therapeutics raises a $3,000,000 series B round from EDBI, Lilly Ventures and Novartis Venture Fund.
April 14, 2008
FORMA Therapeutics raises a $4,000,000 series A round.
2007
FORMA Therapeutics was founded by Alexis Borisy, Nikolai Kley and Steven Tregay.

Funding rounds

People

Name
Role
LinkedIn

Andy Palmer

Advisor

Ariana Wiley

Employee

Dennis France

Employee

Lahiri Vasudevrao Jonnalagadda

Employee

Lynn Walder

Employee

Neal Green

Employee

Tim Haggerty

Employee

Vladislav Zarayskiy

Employee

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Nick Paul
March 30, 2021
FierceBiotech
Forma Therapeutics has presented blinded data on sickle cell disease patients who received 600 mg of FT-4202. The high-dose cohort featured fewer hemoglobin responders than the 300-mg arm, but the safety profile offers encouragement for the ongoing phase 2/3 registrational trial.
BioSpace
November 10, 2020
BioSpace
Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced the European Commission granted Orphan Drug designation to Forma's FT-4202 for the treatment of sickle cell disease (SCD), based on a positive opinion from the Committee for Orphan Medicinal Products of the European Medicines Agency (EMA). FT-4202 was previously

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.